ARCT

Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) medicines and vaccines. Headquartered in San Diego, California, the company operates through its proprietary LUNAR lipid nanoparticle delivery system and STARR mRNA technology platforms, which enable the development of therapeutics for rare diseases, infectious diseases, and oncology. Arcturus's lead product candidate, ARCT-810, targets ornithine transcarbamylase (OTC) deficiency, a rare genetic liver disorder, and is currently in Phase 3 clinical trials. The company's pipeline also includes ARCT-032 for cystic fibrosis lung disease and several COVID-19 vaccine candidates developed in partnership with international collaborators. In 2022, Arcturus received regulatory approval in Japan for KOSTAIVE, its COVID-19 vaccine, representing the company's first commercialized product. The company maintains strategic manufacturing and development collaborations, including partnerships in Southeast Asia for vaccine distribution. Arcturus employs approximately 200 people and operates research facilities in San Diego and manufacturing partnerships globally. The company went public in 2013 and trades on the NASDAQ under the ticker ARCT. With its focus on rare genetic diseases and established mRNA platform technologies, Arcturus positions itself as a vertically integrated biotechnology company advancing multiple clinical programs while maintaining commercial operations in select international markets.